Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART +2.01%70 Gross Margin % is 55.36% as of Mar. 2026, which is 10% below its 10-year median of 61.64. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $23.81 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks worse than 50.25% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Integra Lifesciences Holdings had a gross margin of 55.36% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Integra Lifesciences Holdings Gross Margin % Related Terms
Integra Lifesciences Holdings Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IART vs ATEC, AHCO, INSP: Gross Margin % Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Integra Lifesciences Holdings (IART) has a Gross Margin % of 55.36% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Integra Lifesciences Holdings and its competitors. This is 10% below median its historical median of 61.64. Over the past decade, Integra Lifesciences Holdings' Gross Margin % has ranged from 50.86 to 64.81. According to the industry distribution chart, Integra Lifesciences Holdings ranks #405 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 50.2%.
Is Integra Lifesciences Holdings' Gross Margin % too high?
Integra Lifesciences Holdings' current Gross Margin % of 55.36% is 10% below median its 10-year median of 61.64. Over the past 10 years, this metric has ranged from a low of 50.86 to a high of 64.81. The Medical Devices & Instruments industry median Gross Margin % is 52.05. Integra Lifesciences Holdings' value of 55.36% is 6.4% above this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #405 out of 806 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Gross Margin % compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #405 out of 806 companies for Gross Margin %. This places Integra Lifesciences Holdings in the lower half of its industry. The industry median Gross Margin % is 52.05. Integra Lifesciences Holdings' value of 55.36% is 6.4% above this benchmark. Historically, Integra Lifesciences Holdings' own Gross Margin % has ranged from 50.86 to 64.81 over the past decade. While the company's 10-year median is 61.64 vs. the industry median of 52.05, Integra Lifesciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.05, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current Gross Margin % of 55.36% is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current Gross Margin % is 55.36%, which is 10% below median its own 10-year median of 61.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.81, compared to a current price of $18.78 — trading 21.1% below its estimated fair value. The current Gross Margin % is 55.36%, which is 10% below median its 10-year median of 61.64 and 6.4% above the Medical Devices & Instruments industry median of 52.05. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Gross Margin % is 55.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $18.78 is trading 21.1% below its estimated GF Value™ of $23.81.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
Gross Margin %: 55.36% (10% below median its 10-year median of 61.64)
GF Value™: $23.81 vs. price of $18.78 (21.1% below fair value)
Industry Position: 6.4% above the Medical Devices & Instruments median (#405 of 806)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
